{"product_id":"sandoz-swot-analysis","title":"Sandoz Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSandoz Group’s global generics scale, robust R\u0026amp;D pipeline, and strategic tie-ins with Novartis position it well to capture biosimilars and emerging-market demand, but regulatory pressure, pricing headwinds, and integration risks could constrain margins.\u003c\/p\u003e\n\u003cp\u003eDiscover the full SWOT analysis for deep, research-backed insights, editable Word and Excel deliverables, and strategic recommendations—purchase now to support investment, competitive benchmarking, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Leader in Biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz holds a top-tier global biosimilars position with ~40 approved products across immunology, oncology, and endocrinology and reported biosimilars sales of €1.1bn in 2024.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Sandoz used early-mover timing to capture double-digit market share in key molecules as patents expired, boosting unit volumes 18% year-over-year in 2025.\u003c\/p\u003e\n\u003cp\u003eThis leadership builds a moat via physician trust and \u0026gt;100 regulatory approvals across the US and EU, lowering launch risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Anti-Infectives Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSandoz is a global leader in generic antibiotics, supplying roughly 20% of EU generic systemic antibiotics volumes in 2024 and operating vertically integrated production sites across Europe (incl. Kundl, Austria). Internal manufacturing boosts gross margin resilience—Sandoz reported a 2024 pharma gross margin around 42%—and cuts lead times vs contract manufacturers. As WHO and EU prioritized antimicrobial resistance and supply security in 2024–25, Sandoz is a key supplier for national health systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent Strategic Agility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSince its Oct 2023 spin-off from Novartis, Sandoz has cut costs and sped decisions, reporting a 2024 adjusted EBITDA margin improvement to ~12% from ~8% in 2022, enabling faster capital allocation toward generics and biosimilars.\u003c\/p\u003e\n\u003cp\u003eFreed from competing with Novartis R\u0026amp;D, Sandoz increased capex in 2024 to $450m, prioritizing high-yield manufacturing upgrades and biosimilar pipelines.\u003c\/p\u003e\n\u003cp\u003eIndependence fueled nine small acquisitions and entry into three new markets in 2024, expanding geographic reach and incremental revenue of about $160m.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz operates a sophisticated network of manufacturing sites, mainly in Europe, that meet EU GMP and US FDA standards, enabling production of complex generics and biosimilars requiring specialized processes and high capital.\u003c\/p\u003e\n\u003cp\u003eHigh-quality infrastructure reduced regulatory actions: between 2020–2024 Sandoz reported fewer major inspections issues than lower-cost peers, helping protect ~€7.5bn sales in 2024 from supply disruption risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEurope-centric GMP footprint\u003c\/li\u003e\n\u003cli\u003eProduces complex generics \u0026amp; biosimilars\u003c\/li\u003e\n\u003cli\u003eHigh capex enables advanced tech\u003c\/li\u003e\n\u003cli\u003eLower regulatory action incidents (2020–24)\u003c\/li\u003e\n\u003cli\u003eProtects ~€7.5bn 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad and Diversified Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz offers about 1,000 molecules across cardiovascular, central nervous system, pain, and other areas, reducing revenue swings if one product faces pricing pressure or competition.\u003c\/p\u003e\n\u003cp\u003eThe wide catalog made Sandoz a go-to supplier for hospital systems and pharmacy benefit managers, supporting stable supply contracts and bulk purchasing in 2024–2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,000 molecules portfolio\u003c\/li\u003e\n\u003cli\u003eDiversified across key therapeutic areas\u003c\/li\u003e\n\u003cli\u003eReduces revenue volatility vs single-product risk\u003c\/li\u003e\n\u003cli\u003ePreferred supplier for hospitals and PBMs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: Biosimilars powerhouse—€1.1B sales, €7.5B protected revenue, 12% EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz is a global biosimilars leader (~40 approved; €1.1bn biosimilars sales in 2024), supplies ~20% of EU generic systemic antibiotics volumes, and runs a Europe-centric GMP-compliant manufacturing network protecting ~€7.5bn revenue. Post-Oct 2023 spin-off, adjusted EBITDA rose to ~12% in 2024 and capex reached $450m, funding biosimilar scale-up and nine bolt-on deals adding ~$160m revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars approvals\u003c\/td\u003e\n\u003ctd\u003e~40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars sales\u003c\/td\u003e\n\u003ctd\u003e€1.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU antibiotic share\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProtected revenue\u003c\/td\u003e\n\u003ctd\u003e~€7.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e$450m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition revenue\u003c\/td\u003e\n\u003ctd\u003e~$160m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Sandoz Group, outlining its core strengths and weaknesses alongside market opportunities and external threats shaping its strategic position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT snapshot of Sandoz Group for quick strategic alignment and stakeholder briefings, enabling fast edits to reflect regulatory, R\u0026amp;D, and market shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Generic Price Erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Sandoz Group revenue comes from standard generics, a segment where global tendering and private buyers drove average price declines of ~8–12% annually in 2023–2024, eroding margins.\u003c\/p\u003e\n\u003cp\u003eIn the US, three distributors account for roughly 70% of hospital purchasing, compressing manufacturer margins and forcing discounts that cut gross margins by several percentage points in 2024.\u003c\/p\u003e\n\u003cp\u003eAbsent steady volume growth or new launches—Sandoz reported only 2–3 notable launches in 2024—profitability in the base generics business remains highly sensitive to further price erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Separation Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe full decoupling from Novartis infrastructure has generated about $450m–$600m in one‑time separation costs through 2025, plus ongoing admin complexity; building standalone IT, legal, and global corporate functions cut adjusted net income by roughly 8–12% in 2024–25 and pulled senior management bandwidth away from commercial execution. Until transitional service agreements expire (phased out by 2026–2027), Sandoz may carry overhead 15–25% above peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt Servicing Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpfollowing the spin-off sandoz group carries about billion of net debt pro forma forcing disciplined cash flow management to meet interest and principal constraining free for growth.\u003e\n\u003cpthis leverage limits large-scale acquisitions and speculative r versus debt-free generics peers cutting strategic optionality.\u003e\n\u003cpmaintaining an investment-grade rating bbb- range remains a priority which pressures short-term capital expenditure and dividend flexibility.\u003e\n\u003c\/pmaintaining\u003e\u003c\/pthis\u003e\u003c\/pfollowing\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to European Pricing Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwith a heavy concentration of sales in europe sandoz is highly exposed to localized austerity and reference pricing that cut margins constrain top-line growth eu generics price erosion averaged about annually key markets navigating fragmented regulatory reimbursement systems across states demands large compliance market-access teams limiting fast regional scale-up adding fixed costs. many countries enforce strict caps on off-patent drugs uk italy moved tighter controls pressuring revenues. here the quick math: average pro forma trims revenue.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 EU price erosion ~7% in key markets\u003c\/li\u003e\n\u003cli\u003e€6.5bn regional sales (2024 pro forma)\u003c\/li\u003e\n\u003cli\u003e5% price cut → €325m revenue hit\u003c\/li\u003e\n\u003cli\u003eFragmented 27-state rules raise fixed compliance costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio Concentration in Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSandoz earns about 70% of its 2024 adjusted sales from North America and Europe, regions showing low single-digit growth and pricing pressure; this concentration limits upside versus peers with larger emerging-market exposure.\u003c\/p\u003e\n\u003cp\u003eThe group lags rivals in EM presence—EM sales under 15% in 2024 versus 25–40% for some competitors—raising sensitivity to US\/EU policy shifts and market saturation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% sales from NA\/EU (2024)\u003c\/li\u003e\n\u003cli\u003eEM sales \u0026lt;15% (2024)\u003c\/li\u003e\n\u003cli\u003ePeers EM share 25–40%\u003c\/li\u003e\n\u003cli\u003eHigh policy sensitivity and pricing risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-margin squeeze: generics price erosion, NA\/EU concentration, €6–6.8bn net debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh exposure to low‑margin standard generics (2023–24 price declines ~8–12%) and NA\/EU concentration (~70% sales in 2024) compress margins; US distributor concentration (3 distributors ≈70% hospital purchasing) forces deep discounts. Separation from Novartis added €400m–€550m one‑time costs and raised overhead ~15–25% through 2026, while pro‑forma net debt ≈€6.0–6.8bn (FY2024) limits M\u0026amp;A and R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNA\/EU share\u003c\/td\u003e\n\u003ctd\u003e≈70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEM share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice erosion\u003c\/td\u003e\n\u003ctd\u003e8–12% (generics)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeparation costs\u003c\/td\u003e\n\u003ctd\u003e€400–550m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e€6.0–6.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eSandoz Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752724672889,"sku":"sandoz-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sandoz-swot-analysis.png?v=1772244405","url":"https:\/\/matrixbcg.com\/products\/sandoz-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}